Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising

Yields hit a 24-year high as SpaceX borrows $40 billion for Nvidia chips, and more…

Plan your retirement in 10 steps, SpaceX wants to buy $40B of Nvidia chips, and more…

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annu

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annu

Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and anno

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and r

Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in

Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarte

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annu

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the compan

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS)

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annu

RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outper

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annua

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, g

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data r

Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, excepti

Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a rob

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely

Assetmark Inc. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) in the first

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area.

Fifth Third Bancorp boosted its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 3,958.2% in the fir

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001711279/000171127926000050/krys-20260721.htm

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260720-1484359/1484359_tmhc-av

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and r

TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the pri

HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a B

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

https://www.gov.uk/government/news/mhra-approves-beremagene-geperpavec-vyjuvek-for-the-treatment-of-

Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises

Evercore ISI Group analyst Gavin Clark-Gartner maintains Krystal Biotech (NASDAQ:KRYS) with a Out

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst

Wolfe Research analyst Kalpit Patel initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Pe